ArticleJournal of cachexia, sarcopenia and muscle2015
Differences in food intake of tumour-bearing cachectic mice are associated with hypothalamic serotonin signalling.
Article in Journal of cachexia, sarcopenia and muscle, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 47 citations in OpenAlex.
- Metabolic adaptations of the tumor macroenvironment and their role in cancer progression and survivorship.Genes & development · 2026Review
- Article
- A Novel Mouse Model to Identify Antigen-Specific Immune Responses in Pancreatic Cancer Cachexia.Cancers · 2026Article
- Dependence of energy balance and hypothalamic neuropeptide gene expression on initial tumor load in mice.Frontiers in oncology · 2026Article
- Comprehensive insights into emerging advances in the Neurobiology of anorexia.Journal of advanced research · 2026Review
- A comprehensive review of animal models for cancer cachexia: Implications for translational research.Genes & diseases · 2024Review
- R-ketorolac ameliorates cancer-associated cachexia and prolongs survival of tumour-bearing mice.Journal of cachexia, sarcopenia and muscle · 2024Article
- The atypical β-blocker S-oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model.Journal of cachexia, sarcopenia and muscle · 2023Article
- Leucine Supplementation in Cancer Cachexia: Mechanisms and a Review of the Pre-Clinical Literature.Nutrients · 2022Review
- Pathological features of tissues and cell populations during cancer cachexia.Cell regeneration (London, England) · 2022Review
- Research Progress of Liujunzi Decoction in the Treatment of Tumor-Associated Anorexia.Drug design, development and therapy · 2022Review
- Effects of whole-body vibration training in a cachectic C26 mouse model.Scientific reports · 2021Article
- Liquid Biopsy for Cancer Cachexia: Focus on Muscle-Derived microRNAs.International journal of molecular sciences · 2021Review
- Neural Mechanisms of Cancer Cachexia.Cancers · 2021Review
- Appetite Regulation of TLR4-Induced Inflammatory Signaling.Frontiers in endocrinology · 2021Review
- Cachexia, a Systemic Disease beyond Muscle Atrophy.International journal of molecular sciences · 2020Review
- Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia.Journal of cachexia, sarcopenia and muscle · 2020Review
- Cachexia Disrupts Diurnal Regulation of Activity, Feeding, and Muscle Mechanistic Target of Rapamycin Complex 1 in Mice.Medicine and science in sports and exercise · 2020Article
- Derangements of amino acids in cachectic skeletal muscle are caused by mitochondrial dysfunction.Journal of cachexia, sarcopenia and muscle · 2020Article
- Inter-tissue communication in cancer cachexia.Nature reviews. Endocrinology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnorexia is a common symptom among cancer patients and contributes to malnutrition and strongly impinges on quality of life. Cancer-induced anorexia is thought to be caused by an inability of food intake-regulating systems in the hypothalamus to respond adequately to negative energy balance during tumour growth. Here, we show that this impaired response of food-intake control is likely to be mediated by altered serotonin signalling and by failure in post-transcriptional neuropeptide Y (NPY) regulation.
methodsTwo tumour cachectic mouse models with different food intake behaviours were used: a C26-colon adenocarcinoma model with increased food intake and a Lewis lung carcinoma model with decreased food intake. This contrast in food intake behaviour between tumour-bearing (TB) mice in response to growth of the two different tumours was used to distinguish between processes involved in cachexia and mechanisms that might be important in food intake regulation. The hypothalamus was used for transcriptomics (affymetrix chips).
resultsIn both models, hypothalamic expression of orexigenic NPY was significantly higher compared with controls, suggesting that this change does not directly reflect food intake status but might be linked to negative energy balance in cachexia. Expression of genes involved in serotonin signalling showed to be different between C26-TB mice and Lewis lung carcinoma-TB mice and was inversely associated with food intake. In vitro, using hypothalamic cell lines, serotonin repressed neuronal hypothalamic NPY secretion while not affecting messenger NPY expression, suggesting that serotonin signalling can interfere with NPY synthesis, transport, or secretion.
conclusionsAltered serotonin signalling is associated with changes in food intake behaviour in cachectic TB mice. Serotonins' inhibitory effect on food intake under cancer cachectic conditions is probably via affecting the NPY system. Therefore, serotonin regulation might be a therapeutic target to prevent the development of cancer-induced eating disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.